The combination of targeting proteins involved in DNA damage repair (particularly PARP, DNA-Pk and ATR) and in cell-cycle checkpoint activation (particularly CHK1), have been demonstrated to enhance the radiosensitivity of HNSCC cells in vitro with some evidence also being generated in xenograft models in vivo. The gene discussed is PRKDC; the disease is head and neck squamous cell carcinoma.